ASRS 2021
Real-World & Clinical Trial Patients & Their Outcomes Differ
Oct 21, 2021
Most patients with neurovascular age-related macular degeneration (nAMD) would not qualify for the trials that inform currents standards of care, according to a study presented at the 39th Annual Scientific Meeting of ASRS 2021...
Read MoreOnly One-Third of Medicare Patients With nAMB Stay With Anti-VEGF Treatment
Oct 21, 2021
Only one-third of Medicare beneficiaries with neovascular age-related macular degeneration (nAMB) were “persistent” with anti-VEGF monotherapy treatment each year, according to a study presented at the 39th Annual Scientific...
Read MoreHigh Travel Burden Linked With Under-Representation in nAMD Trials
Oct 21, 2021
Geographic disparities in access to clinical trial sites exist for neovascular age-related macular degeneration (nAMD) in the United States, according to a study presented at the 38th Annual Scientific Meeting of the American...
Read MoreASRS: Medicare Survey Analysis Of Patients With Neovascular Age-Related Macular Degeneration
Oct 12, 2021
Only a third of Medicare beneficiaries were persistent with anti-VEGF monotherapy each year. Overall, two-thirds of patients treated with anti-VEGF at baseline (BL) reported similar or better visual function after 2 years....
Read MoreASRS: Geographic Access Disparities of Clinical Trials in nAMD
Oct 12, 2021
There are geographic disparities in access to clinical trial sites for neovascular age-related macular degeneration (nAMD) in the US. While proximity to urban centers is beneficial for efficiency and retention of subjects, the...
Read MoreASRS: Fluid Quantification From Daily Self-imaging With Home OCT in NV-AMD
Oct 12, 2021
Analysis suggests that daily self-imaging generated images of satisfactory quality for human grading and automated analysis of fluid volume over time permitting a novel paradigm of monitoring. Home OCT may allow personalized...
Read MoreASRS: Apples and Oranges: Comparing “Real-World” And Clinical Trial Outcomes
Oct 12, 2021
The average patient with neovascular age-related macular degeneration (nvAMD) would not qualify for the trials that determine current standards of care. Clinical trial methodology could be to blame for real-world patients having...
Read MoreASRS 2021: Encore Presentation, Intravitreal Gene Therapy for DME
Oct 11, 2021
Data from the INFINITY clinical trial of ADVM-022 in patients with diabetic macular edema (DME) during the American Society of Retina Specialists (ASRS) 39th Annual Scientific Meeting and will be presented an encore presentation...
Read MoreASRS 2021: Oral Retina Drug Shows Favorable Safety, Tolerability
Oct 11, 2021
Positive phase 1 and 2 findings support an ongoing efficacy assessment of the Ref-1 inhibitor for diabetic retinopathy and diabetic macular edema. Investigative oral drug APX3330 has been associated with generally favorable...
Read MoreASRS 2021: Single Gene Therapy Injection for Retinal Degenerative Disease
Oct 11, 2021
Findings from a Phase 1/2a clinical trial of its Multi-Characteristic Opsin (MCO) gene therapy for people blinded by retinitis pigmentosa (RP) were highlighted in two presentations during the 2021 Annual Meeting of the American...
Read MoreASRS 2021: Suprachoroidal delivery for Diabetic Retinopathy
Oct 11, 2021
Initial data from the ongoing Phase II ALTITUDE™ trial of RGX-314 for the treatment of diabetic retinopathy (DR) without center-involved diabetic macular edema (CI-DME) using in-office suprachoroidal delivery was...
Read MoreASRS 2021: Interim Results on Treatment for Advanced X-linked Retinitis Pigmentosa
Oct 10, 2021
Interim safety and clinical activity data from the Phase 1/2 clinical trial of intravitreal 4D-125 in patients with advanced X-linked retinitis pigmentosa (XLRP) was presented in a late-breaking presentation at the American...
Read MorePhase 1/2a Trial of Multi-Characteristic Opsin Gene Therapy
Oct 8, 2021
Phase 1/2a clinical trial of its Multi-Characteristic Opsin (MCO) gene therapy for people blinded by retinitis pigmentosa (RP) will be highlighted in two presentations during the 2021 Annual Meeting of the American Society of...
Read MoreJudy E. Kim, MD, “Annual Meeting is the North Star”
Oct 7, 2021
The American Society of Retina Specialists (ASRS) will host its 39th Annual Scientific Meeting from October 8-12, 2021, at the JW Marriott San Antonio Hill Country Resort and Spa in San Antonio, Texas. According to ASRS, its...
Read MoreWhat to Expect at Upcoming 2021 American Society of Retina Specialists (ASRS)
Oct 7, 2021
The American Society of Retina Specialists (ASRS) will host its 39th Annual Scientific Meeting from October 8-12, 2021, at the JW Marriott San Antonio Hill Country Resort and Spa in San Antonio, Texas. ASRS 2021 serves to...
Read MoreLong-Term Efficacy of Inebilizumab for Neuromyelitis Optica Spectrum Disorder
Oct 1, 2021
Inebilizumab demonstrated favorable long-term safety and efficacy outcomes for patients with neuromyelitis optica spectrum disorder (NMOSD). The 5.5-year follow up results of the open-label extension (OLE) period of the...
Read More